Wang Jie, Shen Yigen, Wang Jiaoni, Xue Yangjing, Liao Lianming, Thapa Saroj, Ji Kangting
Department of Cardiology, The Second Affiliated and Yuying Children's Hospital, Wenzhou Medical University, Wenzhou 325000, Zhejiang, China.
Department of Oncology, Academy of Integrative Medicine, Fujian University of Traditional Chinese Medicine, Fuzhou 3250112, Fujian, China.
Oncotarget. 2017 Jul 11;8(28):46461-46467. doi: 10.18632/oncotarget.17518.
Data on the association between using PDE5 inhibitors and malignant melanoma are conflicting. To estimate the relation of using PDE5 inhibitors with risk of malignant melanoma, Medline (Ovid) and Embase (Ovid) databases were searched up to February 2017, and a random effects model was used to calculate the summary risk estimates. Five observational studies were included. Five studies reports encompassed a total of 15,979 melanoma cases occurring among 1, 188,414 participants. The pooled multivariable-adjusted RR of melanoma in patients with using PDE5 inhibitors was 1.12 (95% CI: 1.03-1.21, I2 = 0.48). Findings from this systematic review support that PDE5 inhibitor use is associated with increased risk of melanoma in ED patients, the result remains inclusive and warrants further study in the future.
关于使用磷酸二酯酶5（PDE5）抑制剂与恶性黑色素瘤之间关联的数据相互矛盾。为了评估使用PDE5抑制剂与恶性黑色素瘤风险之间的关系，检索了截至2017年2月的Medline（Ovid）和Embase（Ovid）数据库，并使用随机效应模型计算汇总风险估计值。纳入了五项观察性研究。五项研究报告共涵盖了1,188,414名参与者中发生的15,979例黑色素瘤病例。使用PDE5抑制剂的患者中黑色素瘤的合并多变量调整风险比为1.12（95%置信区间：1.03 - 1.21，I2 = 0.48）。该系统评价的结果支持在勃起功能障碍（ED）患者中使用PDE5抑制剂与黑色素瘤风险增加有关，该结果仍具有不确定性，未来需要进一步研究。
